July 16, 2026
FOCUS on muscle regeneration. A group at Wash. U. recently reported on a compound designated BE2012 in J. Med. Chem. BE2012 was shown to be a […]
July 14, 2026
In a paper just out in Redox Biology, the authors show that inhibition of 15-OH-PGDH with SW033291 restores redox homeostasis and confers neuroprotection in Parkinson’s disease. […]
June 25, 2026
Focus Biomolecules will be exhibiting at the annual meeting of the International Society for Stem Cell Research in Montreal, July 8 – 10. Stop by our […]
May 28, 2026
FOCUS on Drug Repurposing. Montelukast is a cysteinyl leukotriene receptor (CysLTR1) antagonist currently in use for asthma. In a paper just out in Nature Cancer, a […]
May 8, 2026
FOCUS on PROTACs. On May 1st the first PROTAC, a heterobifunctional protein degrader and a new therapeutic modality, was approved by the FDA. Vepdegestrant (Arvinas’ Veppanu) […]
April 30, 2026
FOCUS on Pancreatic Cancer. In a paper just out in Nature Medicine, the team at Actuate Therapeutics reported the results of their Phase II trial on […]
April 27, 2026
Focus Biomolecules is delighted to announce our 2026 AACR Travel Grant awardees, Shujah Rehman (grad student at The University of Kansas) and Nabamita Boruah (postdoc at […]
April 17, 2026
FOCUS on New Cancer Therapeutic Targets. Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and is largely driven by metabolic disorders such as obesity […]
April 16, 2026
FOCUS on New Drug Approvals. On April 13th the FDA approved Travere Therapeutics’ Sparsentan (Filspari) as the first approved treatment for reduction of proteinuria in adult […]